Monocytes-macrophages in liver injury and regeneration
Download
NHS study permission forms.zip (2.950Mb)
published papers.zip (2.371Mb)
Moore2016.pdf (5.534Mb)
Date
2016-07-02Author
Moore, Joanna Kirsty
Metadata
Show full item recordAbstract
Chronic Liver Disease (CLD) and Acute Liver Failure (ALF) are serious medical syndromes.
Current therapeutic options consist of managing complications, and liver transplant. Even if
liver transplantation is thought to be suitable for CLD or ALF patients, there are not enough
organs available and thus increasingly more deaths occur on the transplant waiting list.
Therefore, there is a pressing need to develop additional therapies.
This thesis firstly systematically reviews trials in autologous cell therapies as possible
treatments for patients with cirrhosis. The published literature is imperfect and the difference
in trial design means it has not been possible to conduct a meta-analysis. Regardless of these
shortcomings, cell therapy is a potentially positive prospect.
In ALF and CLD monocyte-macrophages have diverse roles within the liver. Monocyte and
immune cell changes in ALF are investigated and it is demonstrated for the first time that
patients with paracetamol induced ALF have a significantly altered blood compartment and
that these changes correlate with patient outcome. It is possible that these results may help
stratify which patients may spontaneously survive and which patients may require an
emergency liver transplant. Furthermore, modulation of these changes may improve outcomes
for patients.
The thesis also examines monocyte-macrophages in cirrhotic patients and demonstrates the
feasibility of differentiating cirrhotic patients’ monocytes into functional macrophages,
comparable to healthy volunteers in a Good Manufacturing Practice (GMP) environment. A
first in-man trial using macrophages infused to patients with cirrhosis as a potential new
treatment is also detailed.
Finally, this thesis outlines developmental work for cell therapy in patients with cirrhosis in
the multi-centre REALISTIC trial. Patients were randomly assigned to receive; standard
medical care, Granulocyte Stimulating Factor (GCSF) injections alone or GCSF combined
with repeated stem cell infusion.